{
    "2019-06-01": [
        [
            {
                "time": "",
                "original_text": "恒瑞PD-1获批，百济神州新适应症受理！百亿研发费用下，新一轮市场争夺战要这样打？",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "PD-1",
                        "获批",
                        "百济神州",
                        "新适应症",
                        "受理",
                        "百亿研发费用",
                        "市场争夺战"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【国金行业纵横】中国医药研发蓬勃兴起：转型、创新、发展 | 第22期",
                "features": {
                    "keywords": [
                        "国金行业纵横",
                        "中国医药",
                        "研发",
                        "蓬勃兴起",
                        "转型",
                        "创新",
                        "发展"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}